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motor	cortex,	brainstem,	and	spinal	cord,2	but	also	
astrocytes	 and	 microglia,	 which	 contribute	 to	 the	
spread	 of	 the	 initial	 damage	 and	 disease	 progres-
sion.3-5	 The	 neuropathological	 hallmark	 of	 ALS	 is,	
along	with	corticospinal	tract	degeneration,	a	selec-
tive	loss	of	the	anterior	horns	cells	of	the	spinal	cord	
and	of	cells	in	lower	motor	cranial	nerve	nuclei.	In	
two-thirds	of	patients	the	onset	is	at	the	spinal	level	
(with	hypotrophy	and	weakness	of	upper	or	lower	
limbs	muscles);	 in	one-third	of	patients	 dysphagia	
and	dysarthria	are	the	first	symptoms	(bulbar	onset).	
The	latter	group	shows	in	a	variable	percent	of	cases	
a	moderately	 to	 severe	 impairment	 in	 frontal	 lobe	
functions.3	The	main	clinical	variants	of	ALS	include	
Primary	 Muscular	 Atrophy	 (PMA),	 Primary	 Lateral	
Sclerosis	(PLS),	and	Progressive	Bulbar	Palsy	(PBP).6
Diagnostic	work-up	is	very	complex	and	should	
include	 clinical	 history	 and	 examination,7	 electro-
diagnostic	 tests	 (such	 as	 conventional	 electromy-
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Positron emission tomography neuroimaging 
in amyotrophic lateral sclerosis: what is new?
Amyotrophic lateral sclerosis (ALS) is a neurodegene-
rative disease involving upper and lower motor neu-
rons, extra-motor neurons, microglia and astrocytes. 
The neurodegenerative process results in progressive 
muscle paralysis and even in cognitive impairment. 
Within the complex diagnostic work-up, positron 
emission tomography (PET) represents a valuable ima-
ging tool in the assessment of patients with ALS. PET, 
by means of different radiotracers (i.e. 18F-fluorode-
oxyglucose, 6-[18F]fluoro-L-dopa, [11C]flumazenil) can 
assess the status of the wide range of brain regions 
and neural circuits, which can be affected by ALS. Fur-
thermore, experimental radiocompounds have been 
developed for the evaluation of white matter, which 
plays a role in the progression of the disease. Here we 
present a comprehensive review including in different 
sections the most relevant PET studies: studies investi-
gating ALS and ALS-mimicking conditions (especially 
primary lateral sclerosis and other neurodegenerative 
diseases), articles selecting specific subsets of patients 
(with bulbar or spinal onset), studies investigating pa-
tients with familial type of ALS, studies evaluating the 
role of the white matter in ALS and papers evaluating 
the diagnostic sensitivity of PET in ALS patients.
Key words: Amyotrophic	 lateral	 sclerosis	 -	Positron-emis-
sion	tomography	-	Bulbar	-	Spinal.
Amyotrophic	 lateral	 sclerosis	 (ALS),	 is	 a	 neuro-degenerative	 process	 characterized	 by	 a	 pro-
gressive	impairment	of	motor	function	at	the	bulbar	
and	 spinal	 levels	 with	 a	 not	 yet	 fully	 understood	
aetiology,	resulting	in	progressive	muscle	paralysis.1	
ALS	 involves	 motor	 neurons	 allocated	 in	 primary	
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PET studies in patients with ALS-
mimicking conditions
[18F]FDG-PET	 has	 not	 been	 used	 yet	 in	 clinical	
routine	for	the	evaluation	of	patients	with	ALS,	but	
has	recently	been	proposed	as	a	potential	biomarker	
of	the	disease.26,	27
Neurodegeneration	in	ALS	involves	also	extra-mo-
tor	cerebral	neurons,	including	frontal	and	temporal	
lobes.	Cognitive	 impairment	 in	ALS	shows	clinical,	
pathological	and	genetic	overlap	with	frontotempo-
ral	dementia	 (FTD).10	Abrahams	 et al.3,	 18	 assessed	
the	 cerebral	 blood	 flow	 (rCBF),	 during	 activation	
studies	 performed	 by	 word	 generation	 and	 word	
repetition	(Table	I).	The	authors	demonstrated	that	
ALS	 patients	 with	 cognitive	 impairment	 show	 re-
duced	activation	in	cortical	and	subcortical	regions	
involving	the	dorsolateral	prefrontal,	premotor,	me-
dial	 prefrontal,	 and	 insular	 cortices	 as	well	 as	 the	
anterior	thalamic	nuclear	complex.	Conversely,	non-
demented	ALS	patients	presented	a	relatively	normal	
pattern	of	activation.	These	data	are	expression	of	
an	extramotor	neuronal	involvement	in	some	non-
demented	ALS	patients	that	develops	probably	along	
a	thalamo-frontal	association	pathway.
Renard	et al.31	 investigated	the	[18F]FDG-PET	find-
ings	in	10	patients:	6	ALS	and	4	ALS-FTD	subjects.	The	
authors	reported	hypometabolism	in	the	prerolandic	
medial	frontal	and	orbitofrontal	cortices	as	well	as	in	
the	anterior	 temporal	 lobe	of	 the	ALS	patients.	The	
anterolateral	area	was	the	most	preserved	part	of	the	
frontal	lobe	in	ALS	patients,	compared	to	ALS-FTD	pa-
tients.	Conversely	in	the	ALS-FTD	subgroups,	frontal	
and	temporal	regions	were	highly	hypometabolic	with	
relatively	 spared	 perirolandic	metabolism.	Hypome-
tabolism	 resulted	 unrelated	 to	 the	 disease	 duration.	
No	 differences	were	 evidenced	 at	 [18F]FDG-PET	 re-
garding	metabolism	between	patients	with	symptom	
onset	in	the	limbs	and	patients	with	bulbar	onset.31
The	 group	 of	 Turku	 32	 reported	 on	 a	 patient,	 in	
whom	clinical	evaluation,	MRI	and	[18F]FDG-PET	failed	
to	differentiate	between	FTD	and	Alzheimer’s	disease	
(AD),	 whereas	 a	 subsequent	 [11-C]-Pittsburgh	 com-
pound	B	([11C]PIB-PET)	investigation	was	negative	for	
amyloid	pathology.	The	patient	 later	developed	ALS	
symptoms,	 and	 post-mortem	 neuropathological	 ex-
amination	was	diagnostic	of	FTD-ALS.	Noteworthy,	a	
genetic	C9Orf72	expansion	was	detected.	The	authors	
suggested	 that	 [11C]PIB-PET	may	 facilitate	 the	 early	
differential	diagnosis	between	AD	and	FTD,	including	
AD	 versus	 C9Orf72-FTD/ALS.	 Further	 confirmation	
ography,	nerve	conduction	studies),8	neuroimaging	
including	computed	 tomography	(CT)	or	magnetic	
resonance	 imaging	 (MRI)	 of	 the	 brain	 and	 spinal	
cord	myelogram,9,	10	clinical	laboratory	tests,	muscle	
and/or	nerve	biopsy,	and	genetic	testing.6
Appropriate	 investigations	 are	 needed	 to	 distin-
guish	ALS	from	its	variants,	especially	PLS	11,	12	and	
PMA	13,	14	or	from	diseases	as	frontotemporal	demen-
tia	 (FTD)	 with	 similar	 cognitive	 symptomatology.	
Unrelated	disorders,	such	as	multifocal	motor	neu-
ropathy,	Kennedy’s	disease	or	X-linked	spinobulbar	
muscular	atrophy,	may	present	clinical	features	simi-
lar	to	ALS	or	its	variants	6,	15	and	are	considered	to	be	
responsible	for	diagnostic	error	in	5-10%	of	cases.16
Combination	of	upper	motor	neuron	(UMN)	and	
lower	motor	neuron	(LMN)	impairment	that	cannot	
be	explained	by	any	other	disease	process	by	means	
of	 the	 diagnostic	 work-up,	 together	with	 progres-
sion,	is	suggestive	of	ALS.15
In	 the	 last	 decades,	 neuroimaging	 by	 Positron	
Emission	Tomography	(PET)	has	contributed	to	the	
knowledge	of	functional	changes	occurring	in	ALS	
in	combination	with	both	cognitive	and	motor	 im-
pairment.17	Several	studies	on	the	use	of	PET	in	ALS	
have	been	published	so	far,	mainly	using	18F-fluor-
odeoxyglucose	 ([18F]FDG-PET).18-24	 Most	 imaging	
studies	focusing	on	ALS	used	normal	controls	as	a	
comparison	group	to	highlight	disease	neuropatho-
physiology,	 which	 is	 essential	 to	 validate	 specific	
ALS	 related	metabolic	patterns.3,	 16,	 18,	 20,	 21,	 25-27	 Pa-
tients	with	 ALS	 usually	 demonstrate	 at	 PET	 a	 dif-
fusely	decreased	[18F]FDG	uptake	in	primary	motor	
cortex,	premotor	cortices	and	supplementary	motor	
areas,	 but	 eventually	 also	 in	 parietal	 and	occipital	
lobes.26-28	Clusters	of	relative	hypermetabolism	have	
been	 demonstrated	 in	 the	 mesiotemporal	 regions	
but	also	in	the	occipital	cortex,	cerebellum,	and	up-
per	brain	 stem	of	patients	with	ALS,	 compared	 to	
normal	 controls.20,	 26,	 27	 All	 these	 findings	 reflect	 a	
complex	 neuropathophysiology	 of	 the	 disease	 in-
volving	 degeneration	 of	 gray	 matter	 and	 areas	 of	
reactive	microglial	activation.29,	30
We	will	 review	 the	 scientific	 literature	 reporting	
PET	studies	in	ALS	patients	discussing	the	findings	
in	 five	 separate	 sections:	 i)	 studies	 aiming	 to	 dif-
ferentiate	 ALS	 from	 ALS-mimicking	 conditions;	 ii)	
studies	 focusing	on	ALS	patients	with	spinal	onset	
and	iii)	studies	focusing	on	ALS	patients	with	bulbar	
onset;	 iv)	studies	investigating	the	impact	of	white	
matter	on	the	disease	progression	v)	papers	evaluat-
ing	the	diagnostic	sensitivity	of	PET	in	ALS	patients.
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sporadic	or	familial	ALS	(homozygous	for	the	‘D90A’	
mutation).24	The	differentiation,	according	to	Pringle	
et al.,	is	based	on	the	fact	that	PLS	patients	show	a	
more	marked	neurodegeneration	than	ALS	patients	
of	the	neurons	located	in	the	primary	motor	cortex,	
with	 the	exception	of	 the	 foot	area.35	Besides,	pa-
tients	with	PLS	demonstrate	the	additional	involve-
ment	of	 the	anterior	cingulate	gyrus.24,	34	Lastly,	 in	
their	large-cohort	[18F]FDG-PET	study,	Van	Laere	et 
al.	also	described	more	severe	hypometabolism	in	
the	prefrontal	and	posterior	cingulate	cortex	of	pa-
tients	with	ALS	than	in	patients	with	PLS.27
PET studies on patients with spinal ALS
Patients	with	spinal	onset	represent	the	most	stud-
ied	subgroup	of	ALS	patients	so	far.17,	20,	21,	26,	27,	36-38	
Dalakas	 et al.38	 firstly	 indicated	 that	 hypometabo-
regarding	the	utility	of	amyloid	tracers	has	been	given	
by	Yamakawa	et al.,	 in	a	two	case-study	of	patients	
with	dementia	(FTD	and	AD,	respectively)	associated	
with	MND.	In	the	patient	with	FTD,	the	[11C]PIB-PET	
was	 negative,	while	 in	 the	AD	patient	 [11C]PIB-PET	
documented	presence	of	amyloid	accumulation.33
Using	11C-Flumazenil,	binding	to	the	subunit	of	the	
GABAA	receptor,	Le	Forestier	et al.34	firstly	described	
a	reduction	of	the	synaptic	brain	function	and	a	re-
duced	neuronal	density	 in	 the	primary	motor	 and	
anterior	 cingulate	 cortex	 in	 patients	with	 PLS	 and	
ALS.	Since	PLS	and	ALS	have	features	in	common	in	
respect	 to	the	cortical	dysfunction,34	PET	can	be	a	
useful	 tool	also	in	discriminating	the	two	diseases.	
Even	 though	 [11C]flumazenil	patterns	are	similar	 in	
ALS	 and	 PLS	 patients	 when	 compared	 to	 healthy	
subjects,	differences	can	be	demonstrated	by	a	di-
rect	 comparison	between	 the	 [11C]flumazenil	 bind-
ing	pattern	of	PLS	subjects	and	both	patients	with	
Table I.—Summary of studies evaluating PET in patients with ALS-mimicking conditions.
Authors Year Patients	(N.=) Controls	(N.=)
Disease	duration	
(months) Reduced	uptake Increased	uptake
Pringle et al.35 1992 3	PLS NA 140±55.4 Pericentral	cortex. NA
Abrahams	et al.18 1996 6	ALSci
6	ALSu
	 6 ALSci:	22.7±15.0
ALScu:	25.7±17.0
ALSci	vs.	ALSci/HC:	premotor	
cortex,	dorsolateral	PFC,	temporal	
and	parietal	cortices.
ALSci	vs.	HC:	dorsolateral	PFC,	
insular	cortex	and	thalamus
NA
Le	Forestier	et al.34 2001 5	PLS NA 91.2±39.6 Reduced	CBF	and	BZR	binding	in	
PMC,	prefrontal	and	ACC.
NA
Turner	et al.24 2007 4	PLS
24	ALS
10	ALS-D90A-SOD1
24 PLS:	51±24
ALS:	27±19
ALS-D90A-SOD:	68±59
PLS	vs HC:	reduced	BZR	in	PMC,	
temporal,	parietal	cortex	and	ACC.
ALS/ALS-D90A-SOD	vs	PLS:	
decreased	binding	in	frontal	cortex.
NA
Renard	et al.31 2011 4ALS-FTD NA 12-24 PFC,	temporal	and	parietal	cortex. NA
Yamakawa	et al.33 2012 2	ALS-AD/FTD NA 18±8.5 ALS-FTD:	frontal	and	temporal	
cortex.
ALS-AD:	frontal,	temporal	
and	parietal	cortex,	PCC	and	
precuneus.
NA
Martikainen	et al.32 2014 2	C9ORF72-ALS-FTD NA 24 Frontal,	temporal	and	parietal	
cortex.
NA
Van	Laere	et al.27 2014 70	ALS
7	PLS
4	PMA
20 ALS:	15.2±10.7
PLS:	52.3±52.1
PMA:	12.5±5.7
PLS	vs HC:	reduced	metabolism	in	
PFC,	ACC,	pericentral	cortex	and	
thalamus.
ALS	vs	PLS:	more	pronounced	
hypometabolism	in	ALS	in	PFC	
and	PCC;	more	pronounced	
hypometabolism	in	PLS	in	
sensorymotor	cortex.
PLS	vs HC:	
cerebellum	and	
occipital	cortex.
PLS:	primary	lateral	sclerosis;	NA:	not	available;	ALSci:	ALS	patients	with	cognitive	impairment;	ALScu:	ALS	patients	without	cognitive	impairment;	PFC:	
prefrontal	cortex;	CBF:	cerebral	blood	flow;	BZR:	benzodiazepine	receptor;	PMC:	primary	motor	cortex;	ACC:	anterior	cingulate	cortex;	HC:	healthy	control;	
FTD:	frontotemporal	dementia;	AD:	Alzheimer	dementia;	PCC:	posterior	cingulate	cortex;	PMA:	primary	muscular	atrophy.
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with	the	disease	duration,21	other	authors	found	no	
correlations.31,	37,	40	These	contrasting	findings	may	
be	 related	 to	 the	 small	 sample	of	 the	 investigated	
patients	and	controls.
Cistaro	et al.20	described	in	2012	the	clinical	and	
[18F]FDG-PET	 findings	 of	 19	 patients	 with	 spinal	
onset	 part	 of	 a	 group	 of	 32	 ALS	 patients.	 When	
compared	 to	 healthy	 controls,	 the	 subgroup	with	
spinal	onset	demonstrated	relative	hypometabolism	
in	small	clusters	in	bilateral	lingual	and	in	right	fusi-
form	gyri	and	demonstrated	 less	 severe	hypomet-
abolic	 imaging	 pattern	 than	 patients	 with	 bulbar	
onset.	Direct	comparison	between	spinal	and	bul-
bar	 patients	 showed	 a	 less	 dramatic	 involvement	
of	 prefrontal,	 frontal	 and	 parietal	 regions	 in	 the	
former	group	suggesting	a	different	metabolic	state	
between	the	two	conditions.20	Furthermore,	relative	
hypermetabolism	was	described	in	the	upper	brain	
stem	mainly	in	patient	with	spinal	onset.	Van	Laere	
replicated	the	hypermetabolic	findings	in	the	pos-
terior	 regions,	 including	 the	 cerebellum,	 occipital	
lobe,	brain	stem,	and	mesial	temporal	cortices.27
Lastly,	in	2014,	further	confirmation	of	this	puta-
tive	ALS	metabolic	pattern	came	from	the	study	of	
Pagani	et al.,	who	recruited	136	patients	with	spinal	
ALS.	The	authors	evidenced,	as	previously	described	
in	former	studies,	a	relative	hypermetabolism	in	bi-
lateral	midbrain,	superior	temporal	gyrus,	and	right	
cerebellum	of	patients	with	 spinal-onset	26	 as	well	
as	hypometabolic	areas	in	bilateral	primary	and	as-
sociative	visual	cortex	and	in	bilateral	prefrontal	and	
premotor	cortex.
lism	at	[18F]FDG-PET	imaging	is	a	sign	of	a	neuronal	
malfunctioning	in	ALS	patients	(Table	II).	Hypome-
tabolism	appeared	to	extend	beyond	the	expected	
regions	 (primary	motor	cortex),	 including	also	 the	
surrounding	healthy	neurons.	Later	studies	corrob-
orated	 the	findings	of	Dalakas,	demonstrating	 that	
PET	 abnormalities,	 besides	 affecting	 the	 primary	
motor	 cortex,	 involve	 an	 extensive	 range	 of	 brain	
regions	including	the	frontal	3,	18	and	prefrontal	re-
gions	3,	18,	26,	27	parietal,39	and	temporal	cortex	27	and	
even	 occipital	 lobe.26	 Hatazawa	 et al.21	 showed	 a	
correlation	 between	 altered	 [18F]FDG	 metabolism	
and	length	of	disease	in	ALS	patients.	A	metabolic	
asymmetry	between	right	and	left	lobe,	but	without	
preferential	side,	was	observed	in	patients	with	ALS	
with	upper	 and	 lower	motor	 neuron	 involvement,	
whereas	a	normal	or	near	normal	[18F]FDG	activity	
was	noted	in	four	ALS	patients,	who	presented	with	
only	lower	motor	neuron	involvement.21
Another	 important	hallmark	of	ALS	 is	 the	corre-
lation	between	hypometabolism	at	[18F]FDG-PET	in	
motor	cortex	and	the	characteristic	clinical	features	
of	the	disease	(progressive	muscular	weakness	and	
tendon	 reflex	 changes).	 In	 this	 respect	 an	 inverse	
correlation	has	been	observed	between	metabolism	
in	middle	frontal	gyrus	and	severity	of	neurological	
signs.40
Discrepant	 results	 have	 been	 reported	 between	
severity	 of	 hypometabolism	 and	 disease	 duration.	
While	Hatazawa	 et al.	 reported	 the	 degree	 of	 hy-
pometabolism	in	the	motor-sensory	cortex,	assessed	
in	 a	 small	 group	of	ALS	patients,	 to	be	 correlated	
Table II.—Summary of studies evaluating PET in ALS patients with spinal onset.
Authors Year Patients	(N.=)
Controls	
(N.=)
Disease	duration	
(months) Reduced	uptake Increased	uptake
Dalakas	et al.38 1987 12 11 12-45 Cerebral	cortex	and	basal	ganglia. NA
Hatazawa	et al.21 1988 12 11 12-45 Motor-sensory	cortex,	extra-motor	
cortex	and	putamen.
NA
Ludolph	et al.37 1992 18 12 16.4±10.5 Entire	cortex	and	regionally	in	frontal,	
frontobasal	and	superior	occipital	
cortex.
NA
Cistaro	et al.20 2012 19 20 17.8±16.0 Occipital	cortex. Pons	and	midbrain.
Pagani	et al.26 2013 136 40 4.1 Premotor	cortex,	PFC	and	occipital	
cortex
Midbrain,	cerebellum	and	temporal	
cortex
Cistaro	et al.36 2014 30 40 12.1±8.8 Frontal,	superior	temporal	and	insular	
cortex,	ACC,	PCC,	caudate	and	
thalamus.
Premotor	cortex,	post-central,	
temporal	cortex,	midbrain	and	
occipital	cortex.
Van	Laere	et al.27 2014 48 20 15.2±10 PMC,	PFC,	lateral	frontal	cortex,	ACC	
and	thalamus.
No	differences	reported	between	
spinal	and	bulbar	patients.
Cerebellum,	brain	stem,	occipital	and	
medial	temporal	cortex.
No	differences	reported	between	
spinal	and	bulbar	patients.
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bulbar	 onset.	 Furthermore,	 relative	 hypermetabo-
lism	was	described	in	the	upper	brain	stem	also	in	
patients	with	bulbar	onset	tough	less	evident	than	in	
spinal	patients.	In	ALS	patients	with	bulbar	onset,	a	
significant	relative	decreased	metabolism	was	found	
in	 large	 prefrontal,	 frontal	 and	 parietal	 regions	 as	
compared	with	patients	with	spinal	onset,	suggest-
ing	a	differential	neuropsychological	and	metabolic	
state	 between	 the	 two	 subgroups	 of	 patients.	 On	
the	other	hand,	a	normal	or	near	normal	frontopa-
rietal	[18F]FDG	activity	was	observed	in	ALS	patients	
with	a	spinal	onset.	Once	the	patients	number	was	
substantially	 increased,26	 the	 bulbar	 subgroup	 (59	
patients)	 showed,	 as	 compared	 to	 controls,	 severe	
metabolic	deficit	in	motor,	premotor,	and	prefrontal	
cortex.	Such	hypometabolic	cluster	was	also	found	
in	the	comparison	with	spinal	patients,	though	less	
extended	 and	with	 a	 lesser	 statistical	 significance.	
The	severe	hypometabolism	in	frontal	and	prefron-
tal	 regions	was	 confirmed	 in	another	 recent	 study	
in	which	59	sporadic	ALS	patients	were	investigated	
(Figure	1)	but	where	no	differences	in	metabolism	
were	found	between	patients	with	spinal	and	bulbar	
onset.27	These	findings	speak	in	favour	of	a	different	
metabolic	distribution	in	bulbar	and	spinal	patients,	
stressing	 an	 association	 between	 frontal	 hypome-
tabolism	and	the	prodromal	or	full	blown	cognitive	
decline	in	the	former	group.
PET studies in ALS patients 
carrying specific mutations
In	2014,	Cistaro	et al.36	evaluated	the	[18F]FDG-PET	
pattern	in	15	patients	with	familial	ALS	carrying	the	
GGGGCC	 hexanucleotide	 repeat	 expansion	 in	 the	
PET studies on patients with bulbar ALS
In	 1993,	Kew	 et al.41	 performed	 a	15O	PET	 acti-
vation	 study	aiming	 to	measure	 the	 regional	 cere-
bral	 blood	flow	 (rCBF)	 in	 12	patients	with	ALS,	 7	
of	 them	 with	 bulbar	 onset,	 comparing	 them	 to	 6	
age-matched	controls	(Table	III).	Patients	and	con-
trols	 underwent	 PET	 at	 rest	 and	 during	 execution	
of	stereotyped	and	freely	selected	movements	of	a	
joystick.	The	ALS	patient	showed	an	increased	acti-
vation	in	primary	sensorimotor	cortex	during	activa-
tion	tasks,	whereas	decreased	uptake	was	detected	
at	rest	in	the	sensorimotor	and	lateral	premotor	cor-
tices,	supplementary	motor	area,	anterior	cingulate	
cortex,	paracentral	lobule,	superior	and	inferior	pa-
rietal	cortex.	Noteworthy,	greater	activation	was	ob-
served	in	ALS	patients	in	the	ventral	third	(face	area)	
of	 the	contralateral	primary	sensorimotor	area	and	
in	 the	 adjacent	 contralateral	 ventral	 premotor	 and	
parietal	 association	 regions	 during	 freely	 selected	
joystick	movements.	The	magnitude	of	rCBF	chang-
es	 in	 the	 contralateral	 face	 area	 during	 activation	
was	robustly	correlated	with	the	response	time	and	
the	 presence	 of	 spasticity.	 The	 authors	 argument	
that	time	of	response	is	partially	dependent	on	con-
duction	velocity	along	the	central	motor	pathways.	
Being	spasticity	a	clinical	manifestation	of	damaged	
pathways,	the	relationship	of	these	two	parameters	
with	rCBF	changes	in	the	face	area	suggests	that	a	
cortical	adaptation	to	pyramidal	tract	disruption	may	
be	responsible	for	the	recruitment	of	this	area.41
Cistaro	et al.20	also	evaluated,	among	the	32	pa-
tients	with	ALS,	13	patients	with	bulbar	onset	com-
paring	them	to	19	spinal	ALS	patients	and	22	controls.	
Patients	with	spinal	onset	showed	higher	scores	in	
neuropsychological	examination	than	patients	with	
Table III.—Summary of studies evaluating PET in ALS patients with bulbar onset.
Authors Year Patients	(N.=)
Controls	
(N.=)
Disease	
duration	
(months)
Reduced	uptake Increased	uptake
Kew	et al.41 1993 	 7 	 6 23 Sensorimotor,	lateral	premotor	cortex,	
SMA,	parietal	cortex	and	ACC.
Upon	activation:	PMC,	insula	and	ACC.
Cistaro	et al.20 2012 13 20 17.8±16.0 Inferior,	middle	and	superior	frontal	
cortex,	ACC	and	insula.
Amygdala,	pons,	midbrain.
Pagani	et al.26 2013 59 40 4.1 PMC,	premotor	cortex	and	PFC. Midbrain.
Van	Laere	et al.27 2014 21 20 15.2±10 PMC,	PFC,	lateral	frontal	cortex,	ACC	
and	thalamus.
No	differences	reported	between	spinal	
and	bulbar	patients.
Cerebellum,	brain	stem,	occipital	and	
medial	temporal	cortex.
No	differences	reported	between	
spinal	and	bulbar	patients.
SMA:	supplementary	motor	area.
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ture.	 Since	genetic	 testing	has	become	part	of	 the	
diagnostic	workup,	also	atypical	 cases	beyond	 the	
common	ALS	phenotype	have	been	identified.	Adeli	
et al.42	 reported	 on	 an	 atypical	 case	 of	 C9Orf72-
FTD/ALS,	with	detailed	longitudinal	follow-up.	The	
patient	presented	mild	cognitive	impairment	which	
evolved	into	Alzheimer’s	disease	(AD)	and	later	de-
velopment	of	ALS,	without	behavioural	or	personal-
ity	changes	 in	his	course,	 followed	by	motor	neu-
ron	dysfunction	 about	 six	 years	 after	 the	onset	 of	
cognitive	dysfunction.	The	first	PET	 study	at	pres-
entation	had	 showed	mild	hypometabolism	 in	 the	
medial	 frontal	 and	 lateral	 temporal	 cortices	 (with	
more	prominent	involvement	of	the	left	side),	which	
became	more	severe	during	follow-up.42
Previous	studies	have	also	dealt	with	ALS	patients	
carrying	 mutation	 of	 SOD1,	 a	 gene	 encoding	 the	
enzyme	copper,	zinc	superoxide	dismutase	protein	
(Cu/Zn-SOD).24,	43-45	Cu/Zn-SOD,	widely	expressed	
in	numerous	subsets	of	cells	of	central	and	peripher-
al	nervous	systems,	plays	a	fundamental	role	in	pro-
tecting	cells	against	 reactive	oxygen	species,46	and	
mutated	forms	of	the	protein	can	result	in	apoptotic	
death	 of	motor	 neuron	 cells.47	With	 regard	 to	 the	
evidence	 that	 spinal	motor	neurons	and	dopamin-
ergic	 neurons	 are	 among	 the	 cells	with	 the	 high-
est	 expression	 of	 Cu/Zn-SOD,48	 Przedborski	 et al.	
postulated	a	subliclinical	nigrostriatal	dysfunction	in	
SOD1-mutated	patients	43	and	investigated	by	6-[18F]
fluoro-L-dopa	 ([18F]FDOPA)	 PET	 14	 familial	 ALS	
(FALS)	patients	(7	with	and	7	without	SOD1-	muta-
tion).	Despite	the	absence	of	statistically	significant	
C9Orf72	 gene	 (Table	 IV).	 The	 authors	 compared	
the	15	patients	with	familial	ALS	with	a	group	of	12	
patients	 with	 ALS	 and	 comorbid	 FTD	without	 the	
C9Orf72	 expansion	 (ALS-FTD),	with	 30	 cognitively	
normal	 ALS	 patients	 and	 wth	 40	 normal	 controls.	
Among	the	4	groups,	patients	carrying	the	C9Orf72	
mutation	 showed	 the	more	 severe	 involvement	 of	
the	central	nervous	system,	with	significant	hypome-
tabolism	in	the	anterior	and	posterior	cingulate	cor-
tex,	 insula,	 caudate,	 certices	 thalamus	 and	 the	 left	
frontal	and	superior	temporal	certices,	and	hyperme-
tabolism	 in	 the	midbrain,	 bilateral	 occipital	 cortex,	
globus	pallidus,	and	left	inferior	temporal	cortex.36
In	 the	 same	 year	 Van	 Laere	 27	 investigated	 the	
possible	 presence	 of	 specific	 metabolic	 signature	
at	 [18F]FDG-PET	 imaging	 in	 a	 large	 group	 (N.=81)	
of	 patients	 with	 suspected	 diagnosis	 of	 ALS.	 The	
diagnosis	 of	 pure	 ALS	 was	 made	 in	 seventy	 sub-
jects,	among	which	11	carried	the	C9orf72	mutation.	
Whereas	overall	hypometabolism	was	evidenced	in	
the	perirolandic	region	and	with	variable	degree	in	
the	prefrontal	cortex	in	the	majority	of	patients,	pa-
tients	with	C9orf72	mutation	demonstrated	greater	
relative	 hypometabolism	 in	 the	 thalamus,	 prefron-
tal	and	posterior	cingulate	certices	when	compared	
with	C9orf72-negative	ALS	patients.27
Taken	 together	 these	 studies	 concordantly	 sug-
gest	a	more	severe	central	nervous	system	involve-
ment	 in	patients	 carrying	 the	C9orf72	mutation	 as	
compared	 to	 both	 sporadic	ALS	 and	ALS-FTD	pa-
tients	underscoring	the	correlation	between	changes	
at	[18F]FDG-PET	and	the	severity	of	the	clinical	pic-
Figure	1.—PET	findings	in	119	ALS	patients	compared	with	30	controls.	Statistically	significant	differences	(P<0.05	FDR)	are	highlighted	on	
a	MRI	T1	template.	Hypermetabolism:	left:	sagittal	view;	center	and	right:	coronal	views.	Significant	corrected	clusters	are	seen	in	midbrain,	
medial	temporal	lobes	and	cortispinal	tracts.
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ter	 of	 decreased	 of	 [11C]flumazenil	 binding	 at	 the	
left-fronto	temporal	junction,	which	he	named	“the	
clinical	horizon”,	possibly	reflecting	cortical	modi-
fications	appearing	before	the	onset	of	the	clinical	
signs.44	 There	 is	 evidence	 that	 patients	 with	 spo-
radic	 ALS	 demonstrate	 a	 relative	 reduced	 cortical	
inhibition	at	[11C]flumazenil-PET	a	detectable	in	mo-
tor	 and	motor	 associative	 areas,	 compared	 to	 pa-
tients	with	D90A	mutation	45	supporting	the	role	of	
excitotoxic	pathogenic	mechanisms	in	determining	
the	different	survival	between	the	two	groups.45,	51	
The	diverse	cortical	vulnerability	of	D90A-mutated	
patients	was	also	explored	in	a	comparative	study	
with	a	small	group	of	PLS	patients,	highlighting	a	
relative	 decreased	 [11C]flumazenil	 binding	 pattern	
in	the	anterior	and	orbito-frontal	regions	of	D90A-
mutated	patients.24
Studies on the impact of white 
matter and neuroinflammation on 
the evolution of ALS disease
There	 are	many	data	 in	 literature	 suggesting	 an	
active	role	of	white	matter	in	the	progression	of	ALS	
disease.	Some	authors	have	postulated	that	 the	 in-
creased	 number	 of	 astrocytes	 found	 in	 ALS	 brain	
may	be	due	to	the	colonization	of	the	empty	spaces	
differences	between	the	two	groups	of	patients	re-
garding	 the	striato-occipital	 ratios	(SOR),	five	FALS	
patients	 showed	 abnormal	 [18F]FDOPA	 uptake,	
confirmed	 at	 post-mortem	 by	 nigrostriatal	 degen-
eration.	Two	out	of	5	patients	with	abnormal	 [18F]
FDOPA-PET	 imaging	 presented	 clinical	 features	 of	
Parkinson’s	disease	(bradykinesia),	and	2/5	patients	
without	clinical	signs	showed	SOR	values	within	the	
range	of	early	Parkinson’s	disease.	Furthermore,	the	
authors	did	not	find	any	correlation	between	abnor-
mal	SOR	values,	age	at	onset	or	duration	of	symp-
toms.	This	 last	finding	 is	 in	contrast	with	 those	of	
Takahashi	et al.49	who	found	an	inverse	correlation	
between	 reduced	 [18F]FDOPA	uptake	 and	duration	
of	 symptoms	but	 in	 a	population	of	 sporadic	ALS	
patients.
Among	 the	 several	 known	 SOD1	 gene	 muta-
tions,46	 the	 ‘D90A’	 mutation	 is	 associated	 with	 a	
slower	progression	than	usual	of	the	disease	and	a	
longer	survival.50	Patients	with	D90A	mutation	seem	
to	 show	 a	 different	 pattern	 of	 cortical	 neuronal	
loss	or	dysfunction	at	[11C]flumazenil	PET	imaging,	
compared	 to	 patients	 with	 sporadic	 ALS	 (premo-
tor	and	motor	cortices	and	posterior	motor	associa-
tive	areas).44	Turner	detected	a	decreased	uptake	in	
the	 frontal	 lobe	 of	 the	 dominant	 hemisphere	 and	
in	 anterior	 cingulate	gyrus	 in	 10	 symptomatic	pa-
tients	carrying	D90A	mutation	and	a	 smaller	clus-
Table IV.—Summary of PET studies in ALS patients carrying specific mutations.
Authors Year Patients	(N.=) Controls	(N.=)
Disease	duration	
(months) Reduced	uptake Increased	uptake
Przedborski	et al.43 1996 14 14 45.36±28.7 7	fALS	without	SOD-1	mutation:	
putamen.
5	fALS	with	SOD-1	mutation:	
caudate	and	putamen.
NA
Turner	et al.44 2005 10 24 68±59 Frontal	lobe	and	ACC NA
Turner	et al.45 2005 	 9 NA 65±57 PMC	and	SMA. NA
Turner	et al.24 2007 10	ALS-D90A-SOD1
24	ALS
PLS
24 53±12 ALS/ALS-D90A-SOD	vs	PLS:	
decreased	binding	in	frontal	cortex.
NA
Adeli	et al.42 2014 Ú1 NA 24 Pre-	and	dorsolateral	frontal	and	
temporal	cortex
NA
Cistaro	et al.36 2014 15	C9orf72-positive 40 10.1±7.3 Frontal,	superior	temporal	and	
insular	cortex,	ACC,	PCC,	caudate	
and	thalamus
Midbrain		
and	occipital	cortex
Van	Laere	et al.27 2014 11	C9orf72-positive
59	C9orf72-negative
20 C9orf72-positive	
13.8±10.2
C9orf72-negative
15±10.6
C9orf72-positive	ALS	vs.	HC	=	
bilaterally	in	the	thalamus,	posterior	
cingulate	and	precuneus	C9orf72-
positive	ALS	vs.	C9orf72-negative	
ALS:	thalamus	and	PCC.
NA
fALS:	familial	ALS.
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left	by	the	dead	neurons,22,	52	whereas	a	few	studies	
have	showed	a	link	between	increased	astrocytosis	
in	areas	of	neurodegeneration	 in	ALS	patients	and	
disease	progression.19,	53
These	findings	are	in	agreement	with	the	evidence	
that	glucose	is	not	consumed	only	by	neurons	and	
that	its	uptake	therefore	does	not	exclusively	reflect	
neural	 activity.	 Conversely	 astrocytes	 also	 play	 an	
important	 role	 in	 the	 regulation	of	glucose	utiliza-
tion	being	the	major	[18F]FDG	uptake	determinant	in	
the	astrocyte-neuron	functional	unit.54,	55
Turner	 et al.23	 performed	 a	 study	 in	 10	 patients	
with	ALS	and	demonstrated	an	extensive	microglial	
activation	 by	 means	 of	 11C-(R)-PK11195,	 a	 ligand	
for	 the	18kDa	translocator	protein	(TSPO)	(formerly	
known	 as	 the	 peripheral	 benzodiazepine	 binding	
site),	expressed	on	the	mitochondrial	membrane	of	
activated	microglia	(Table	V).	Uptake	was	found	in	
the	motor	cortex,	pons	and	thalamus,	and	appeared	
to	be	related	with	the	burden	of	upper	motor	neuron	
clinical	 signs.23	 The	 group	 of	 Johansson	 provided	
evidence	 that	astrocytosis	may	be	depicted	 in vivo	
in	ALS	patients	and	highlighted	the	utility	of	11C-(L)-
deprenyl-D2	 (DED),	 targeting	 the	 enzyme	MAO-B,	
primarily	located	in	astrocytes.56	The	authors	docu-
mented	uptake	of	DED	in	pons	and	white	matter	in	7	
ALS	patients	and	emphasized	the	need	of	future	stud-
ies	combining	[11C](R)-PK11195	and	[11C]DED	PET	to	
clarify	the	spatial	and	temporal	relationship	between	
microglial	activation	and	astrocytosis	in	ALS.
A	further	study	with	a	glial	tracer	was	performed	
by	Corcia	et al.57	who	evaluated	neuroinflammation	
in	ALS	patients	using	[18F]-DPA-714,	a	more	recently	
developed	 TSPO	 radioligand	 with	 high	 signal-to-
noise	ratio.	A	significant	increase	of	distribution	vol-
ume	ratio	values,	corresponding	to	microglial	activa-
tion,	was	shown	in	the	primary	and	supplementary	
motor	 and	 temporal	 cortices,	 thus	 suggesting	 the	
use	of	this	tracer	as	a	promising	biomarker	of	neu-
roinflammation.57
Figure	2.—Three-dimensional	rendering	showing	those	regions	in	
which	[18F]FDG	uptake	was	significantly	higher	in	CTR	(N.=20)	as	
compared	with	ALS	patients	(N.=59)	(threshold	P<0.0001uncorrected).	
Top	row	left:	medial	left	view;	top	row	right:	medial	right	view;	
second	row	left:	posterior	view;	second	row	right:	 frontal	view;	
third	 row	 left:	 right-side	 view;	 third	 row	 right:	 left-side	 view;	
bottom	row	left:	view	from	below;	bottom	row	right:	view	from	
above.
Table V.—Summary of PET studies evaluating white matter in ALS patients.
Authors Year Patients	(N.=)
Controls	
(N.=) Disease	duration	(months) Reduced	uptake Increased	uptake
Turner	et al.23 2004 10 14 25.3±11.6 NA PMC,	pons,	dorsolateral	PFC,	thalamus.
Johansson	et al.56 2007 	 7 	 7 27.6±13.6 NA Pons	and	WM.
Corcia	et al.57 2012 10 	7 11.7;	5-27 NA PMC,	SMA	and	temporal	lobe.
WM:	white	matter.
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Future perspectives and conclusions
Despite	 the	 lack	of	multicentre	studies	 to	evalu-
ate	 the	 utility	 of	 neuroimaging	 in	 differentiating	
ALS	 from	 ALS-mimicking	 conditions,	 an	 appropri-
ate	assessment	of	sensitivity	and	specificity	of	 [18F]
FDG-PET	is	now	possible	due	to	the	large	patients	
cohorts	 recruited	by	 some	of	 the	 centres	 involved	
in	ALS	research.26,	27	A	high	accuracy	in	diagnosing	
ASL	patients	and	possibly	discriminating	them	from	
ALS-mimicking	diseases	patients	will	be	essential	to	
recruit	appropriate	subjects	for	clinical	trials,	to	de-
velop	new	therapies	and	to	identify	possible	disease	
familiarity	allowing	early	interventions.
Functional	 imaging	 is	 likely	 to	 increment	 in	 the	
next	future	its	role	in	the	evaluation	of	patients	af-
fected	 by	ALS	 and	 probably	 [18F]FDG-PET/CT	will	
continue	to	be	an	imaging	tool	of	outstanding	im-
portance	in	the	evaluation	of	ALS	in	the	next	dec-
ade.	Last	but	not	least,	the	introduction	of	PET/MRI	
scanners	in	clinical	setting	would	contribute	to	bet-
ter	understand	the	ALS	pathophysiology	combining	
morphological	 and	 functional	 information,	 which	
may	also	include	novel	markers	for	neuroinflamma-
tion	or	effects	on	neurotransmission.61
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gani	 et al.26	 speculated	 that	 the	 hypermetabolism	
found	in	midbrain	and	corticospinal	tracts	(Figure	2)	
might	be	due	to	astrocytosis	resulting	in	a	relatively	
higher	glucose	uptake	as	compared	 to	 the	normal	
condition	in	which	the	amount	of	astrocytes	in	such	
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Diagnostic sensitivity analyses
As	in	other	neurodegenerative	disease,58	the	use	
of	machine	learning	tools	is	rapidly	increasing,	in	or-
der	to	differentiate	ALS	from	mimicking	syndromes.	
Machine	learning	identifies	complex	patterns	auto-
matically	and	may	help	nuclear	medicine	physicians	
make	 intelligent	 decisions	 on	 the	 analysis	 of	 PET	
images,	which	may	be	combined	with	other	 infor-
mation	 (structural,	 clinical,	 genetical),	 also	 known	
as	radiomics.59
In	2010,	Filippini	et al.	used	in	a	MRI	study	dis-
criminant	analysis,	combining	radial	diffusivity,	frac-
tional	anisotropy	and	voxel-based	morphometry,	in	
a	 group	 of	 ALS	 patients	 reporting	 92%	 sensitivity,	
88%	specificity,	and	90%	accuracy.60
Only	 two	 studies	 analyzed	 the	 diagnostic	 per-
formance	of	PET	in	ALS	patients	due	to	the	rarity	of	
disease	and	the	small	sample	in	most	studies.
Van	Laere	et al.27	evaluated	the	diagnostic	ability	
of	[18F]FDG-PET	in	a	large	cohort	of	81	patients	with	
suspected	diagnosis	of	ALS.	Without	a priori	knowl-
edge	PET	correctly	classified	100%	of	controls,	89%	
of	ALS	patients	and	71%	patients	with	PLS.27	A	direct	
comparison	between	ALS	and	PLS,	using	a	support	
vector	machine	 approach	 and	 88	VOIs,	 showed	 a	
high	accuracy	(89.7%),	the	prefrontal	cortex,	thala-
mus,	posterior	cingulate,	and	anterior	cingulate	be-
ing	the	most	discriminating	regions.
Recently	Pagani,	et al.26	reported	for	[18F]FDG-PET	
implementing	 the	 generalized	 linear	 discriminant	
model	a	sensitivity	of	95%	and	a	specificity	of	83%	
in	discriminating	ALS	patients	from	healthy	controls	
in	the	largest	study	published	so	far,	including	195	
ALS	 subjects	 and	 40	 controls.	 The	 study	 analyses	
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rior	temporal	gyrus	and	hippocampus.
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